Volume : 10, Issue : 02, February – 2023

Title:

46.REVIEW ON HERBAL DRUGS USED IN TREATMENT OF ‘MUCORMYCOSIS’
‬

Authors :

Ashutosh G. Puri, Sainath N.Kharbe, Datta M.Ghumatkar, Dr.Monika Jadhao

Abstract :

Across the globe and mainly in India, several cases of Mucormycosis in people with COVID19 have been increasingly reported. The rise in the number of cases, the emergence of new risk factors and causative agents, mortality associated with mucormycosis in India is considerably high and the challenges in managing the disease.
Mucormycosis is a rare but often fatal disease caused by certain fungi. It is sometimes called zygomycosis or phycomycosis. It is an opportunistic infection that typically develops in patients with weakened immune systems, diabetes, kidney failure, organ transplants or chemotherapy for cancer.
Mucormycosis is a rare angio invasive infection mainly recognized in immuno-compromised patients which occurs due to the fungi mucorales. This rare fungal infection can be classified into rhino-orbitocerebral, cutaneous, disseminated, gastrointestinal and pulmonary types.
In this we discuss about the herbal drugs used in the treatment of Mucormycosis. For mucormycosis,it is very important to get treatment as if left untreated this can prove fatal.In this article we will discuss mucormycosis,its causative agents and symptoms of mucormycosis infection and how it can be managed using Ayurvedic formulations

Cite This Article:

Number of Downloads : 10

References:

1) Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. (December
2012).”Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011″. The New England Journal of Medicine. 367 (23): 2214–25.
2) Prakash H, Chakrabarti A (March 2019). “Global Epidemiology of Mucormycosis”. Journal of Fungi. 5 (1): 26.
3) Skiada A, Pavleas I, Drogari-Apiranthitou M (November 2020). “Epidemiology and Diagnosis of Mucormycosis: An Update”. Journal of Fungi. 6 (4): 265.
4) Dannaoui E, Lackner M (December 2019). “Special Issue: Mucorales and Mucormycosis”. Journal of Fungi. 6 (1): 6.
5) Mohammadi R, Nazeri M, Sayedayn SM, Ehteram H. “A successful treatment of rhinocerebral mucormycosis due to Rhizopusoryzae.” Journal of research in medical sciences: The Official Journal of Isfahan University of Medical Sciences, 2014; 19(1): 72.
6) Kwon-Chung KJ. “Taxonomy of fungi causing mucormycosis and entomophthoramycosis (zygomycosis) and nomenclature of the disease: molecular mycologic perspectives.” Clinical Infectious Diseases, 2012; 54 (suppl_1): S8- 15.

7) Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP.” Epidemiology and outcome of zygomycosis: a review of 929 reported cases.” Clinical Infectious Diseases, 2005; 41(5): 634-53.
8) Bitar D, Van Cauteren D, Lanternier F et al. “Increasing incidence of zygomycosis (mucormycosis), France, 1997– 2006.” Emerg Infect Dis. 2009; 15: 1395–1401.
9) Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. “Epidemiology and clinical manifestations of mucormycosis.” Clinical Infectious Diseases, 2012; 54(suppl_1): S23-34.
10) Waldorf AR. “Pulmonary defense mechanisms against opportunistic fungal pathogens.” Immunol Ser., 1989; 47: 243–271
11) Rammaert B, Lanternier F, Poirיe S, Kania R, Lortholary O. “Diabetes and mucormycosis: a complex interplay.” Diabetes & metabolism, 2012; 38(3): 193-204.
12) Meyer BR, Wormser G, Hirschan SZ, et al. “Rhinocerebralmucormycosis: premortem diagnosis and therapy.” Arch. Intern. Med., 1979; 139: 557.
13) Gale GR, Welch AM. “Studies of opportunistic fungi. I. Inhibition of Rhizopusoryzae by human serum. Am.” J. Med. Sci., 1961; 241: 604–12.
14) Waldorf AR, Ruderman N, Diamond RD. “Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus.” J. Clin. Invest., 1984; 74: 150 60.
15) Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. “Pulmonary mucormycosis: results of medical and surgical therapy.” Ann. Thorac. Surg., 1994; 57(4): 1044- 50.
16) Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. “Infections in patients with diabetes mellitus. N. Engl.” J Med., 1999; 341(25): 1906- 12.
17) Bhansali A, Sharma A, Kashyap A, Gupta A, Dash RJ. “Mucorendophthalmitis.” ActaOphthalmol Scand., 2001; 79(1): 88- 90.
18) G.Sai Sri Lakshmi, K.Mahima Prasanna, Ch.Supriya ,K.Poojamanisai, K.Krishnaveni, corresponding author: Department of Pharmaceutical Analysis, Nirmala college of pharmacy, Acharya Nagarjuna University, Atmakur, Mangalagiri,Guntur,522503.“A review on herbal drugs used in treatment of mucormycosis.” Department of Pharmaceutical Analysis, Nirmala college of pharmacy, Atmakur, Mangalagiri, Guntur, Andhra Pradesh, India.
19) Koushlesh Kumar mishra, Chanchal deep kaur, Anil Kumar sahu, RajinikantPanik, Pankaj kashyap, Saraswatiprasadmishra and Shweta dutta.“Medicinal plants having Antifungal properties.”
20) Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP. “Epidemiology and outcome of zygomycosis: a review of 929 reported cases.” Clinical Infectious Diseases, 2005; 41(5): 634-
53.
21) Bitar D, Van Cauteren D, Lanternier F et al. “Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006.” Emerg Infect Dis., 2009; 15: 1395–1401.
22) Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. “Epidemiology and clinical manifestations of mucormycosis.” Clinical Infectious Diseases, 2012; 54(suppl_1): S23-34.
23) Waldorf AR. “Pulmonary defense mechanisms against opportunistic fungal pathogens.” Immunol Ser., 1989; 47: 243–271
24) Rammaert B, Lanternier F, Poirיe S, Kania R, Lortholary O. “Diabetes and mucormycosis: a complex interplay. “ Diabetes & metabolism, 2012; 38(3): 193-204.
25) Meyer BR, Wormser G, Hirschan SZ, et al. “Rhinocerebral mucormycosis: premortem diagnosis and therapy.” Arch. Intern. Med., 1979; 139: 557.
26) Gale GR, Welch AM. Studies of opportunistic fungi. I. “Inhibition of Rhizopus oryzae by human serum. Am.” J. Med. Sci., 1961; 241: 604–12.
27) Waldorf AR, Ruderman N, Diamond RD. “Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus.” J. Clin. Invest., 1984; 74: 150 60.
28) Tedder M, Spratt JA, Anstadt MP, Hegde SS, Tedder SD, Lowe JE. “Pulmonary mucormycosis: results of medical and surgical therapy.” Ann. Thorac. Surg., 1994; 57(4):
1044- 50.
29) Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. “Infections in patients with diabetes mellitus.” N. Engl. J Med., 1999; 341(25): 1906- 12.
30) Bhansali A, Sharma A, Kashyap A, Gupta A, Dash RJ. “Mucor endophthalmitis.” Acta Ophthalmol Scand. 2001; 79(1): 88- 90.
31) Tsaousis G, Koutsouri A, Gatsiou C, Paniara O, Peppas C, Chalevelakis G. “Liver and brain mucormycosis in a diabetic patient type II successfully treated with liposomal amphotericin B.” Scand. J. Infect. Dis., 2000; 32(3): 335- 7.
32) Waldorf AR, Levitz SM, Diamond RD. “In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus.” J. Infect. Dis., 1984; 150(5): 752-60.
33) Artis WM, Fountain JA, Delcher HK. “A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability.” Diabetes, 1982; 31: 109–14.
34) Cohen SG, Greenberg MS. “Rhinomaxillary mucormycosis in a kidney transplant patient.” Oral Surg. Oral Med. Pathol., 1980; 50: 33–8.
35) Marchevskey AM, Bottone EJ, Geller SA. “The changing spectrum of disease etiology and diagnosis of mucormycosis.” Human Pathology, 1980; 11: 457.
36) Marty FM, Cosimi LA, Baden LR. “Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell trans-plants.” N. Engl. J. Med., 2004; 350: 950–952.
37) Safder S, Carpenter JS, Roberts TD, Bailey N. The black turbinate sign: an early MR imaging finding Of nasal mucormycosis. AJNR. Amer. J. Neuroradiol., 2010; 31: 771-774.
38) Rogers WD. Facial paralysis and epistaxis in a diabetic: a typical presentation for rhinocerebral mucormycosis. Ann. Emerg. Med., 1984; 13: 560 –1
39) Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin.
Infect. Dis., 2005; 41: 60-66.
40) Hamilos G, Samonis G, Kontoyiannis DP. Pulmonary mucormycosis. Semin. Respir. Crit. Care Med., 2011; 32: 693–702
41) Jensen HE, Salonen J, Ekfors TO. The use of immunohistochemistry to improve sensitivity and specificity in the diagnosis of systemic mycoses in patients with haematological malignancies. J. Pathol.,1997; 181(1): 100-5
42) Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clinical Infectious Diseases, 2012; 54(suppl 1):S55-60.
43) Sciubba JJ, Regezi JA, Rogers RS. PDQ oral disease:diagnosis and treatment. PMPH-USA; 2002.
44) Petrikkos G, Skiada A, Sambatakou H et al. “Mucormycosis:ten-year experience at a tertiary-care center in Greece.” Eur. J. Clin. Microbiol. Infect Dis., 2003; 22: 753–756.
45) Nithyanandam S, Jacob MS, Battu RR, Thomas RK, Correa MA, D’Souza O. “Rhinoorbito-cerebral mucormycosis. A retrospective analysis of clinical features and treatment outcomes.” Ind. J. Ophthalmol., 2003; 51: 231–236
46)Sipsas N, Gamaletsou M, Anastasopoulou A, Kontoyiannis D. “Therapy of mucormycosis.” Journal of Fungi, 2018; 4(3): 90.